Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study

Hessa Al-Wayli, Hessa Al-Wayli

Abstract

Background: To evaluate the role of botulinum toxin type A (BTX-A) in the treatment of pain associated with nocturnal bruxism.

Material and methods: Fifty subjects reporting nocturnal bruxism were recruited for a randomized clinical trial. Twenty five bruxers were injected with botulinum toxin in both masseters, and twenty five were treated with traditional methods of treating bruxism. Patients were evaluated at 3rd week, 2nd and 6th month and one year after injection and then used to calculate bruxism events. Bruxism symptoms were investigated using questionnaires.

Results: Mean pain score due to Bruxism events in the masseter muscle decreased significantly in the botulinum toxin injection group A (P =0.000, highly significant). However, in the conventional treatment group, mean pain score does not show improvement with time (p>0.05).

Conclusions: Our results suggest that botulinum toxin injection reduced the mean pain score and number of bruxism events, most likely by decreasing the muscle activity of masseter rather than affecting the central nervous system. Key words:Temporomandibular pain, nocturnal bruxism, botulinum toxin.

Conflict of interest statement

The author declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Points of application of BOTOX in the masseter muscle.

References

    1. Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord. 2000;15:171–3.
    1. Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016;38:5.
    1. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015;33:291–8.
    1. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2014:2151090314Y0000000022.
    1. Sevim S, Kaleağası H, Fidancı H. Sleep bruxism possibly triggered by multiple sclerosis attacks and treated successfully with botulinum toxin: Report of three cases. Mult Scler Relat Disord. 2015;4:403–5.
    1. Azam A, Manchanda S, Thotapalli S, Kotha SB. Botox Therapy in Dentistry: A Review. J Int Oral Health. 2015;7:103–5.
    1. Malcmacher L. Bruxism--Are You Helping or Hurting Your Patients? J N J Dent Assoc. 2015;86:14–6.
    1. Manfredini D, Ahlberg J, Winocur E, Lobbezoo F. Management of sleep bruxism in adults: a qualitative systematic literature review. J Oral Rehabil. 2015;42:862–74.
    1. Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999;17:196–201.
    1. Pedemonte C, Pérez Gutiérrez H, González E, Vargas I, Lazo D. Use of onabotulinumtoxinA in post-traumatic oromandibulardystonia. J Oral Maxillofac Surg. 2015;73:152–7.
    1. Malcmacher L. Are you prescribing bruxism appliances? Dent Today. 2014;33:126–9.
    1. Kesikburun S, Alaca R, Aras B, Tuğcu I, Tan AK. Botulinum toxin injection for bruxism associated with brain injury: case report. J Rehabil Res Dev. 2014;51:661–4.
    1. Shim YJ, Lee MK, Kato T, Park HU, Heo K, Kim ST. Effects of botulinum toxin on jaw motor events during sleep in sleep bruxism patients: a polysomnographicevaluation. J Clin Sleep Med. 2014;10:291–8.
    1. Lobbezoo F, Ahlberg J, Glaros AG, Kato T, Koyano K, Lavigne GJ. Bruxism defined and graded: an international consensus. J Oral Rehabil. 2013;40:2–4.
    1. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7:31–9.
    1. Garcia-Ruiz PJ. Applications of botulinum toxin in Neurology. Med Clin (Barc) 2013;141:33–6.
    1. Kreyden OP, Geiges ML, Böni R, Burg G. Botulinum toxin: from poison to drug. A historical review. Hautarzt. 2000;51:733–7.
    1. Laskin DM. Botulinum toxin A in the treatment of myofascial pain and dysfunction: the case against its use. J Oral Maxillofac Surg. 2012;70:1240–2.
    1. Manfredini D, Lobbezoo F. Relationship between bruxism and temporomandibular disorders: a systematic review of literature from 1998 to 2008. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:e26–50.
    1. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26:785–93.
    1. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J. 2012;62:1–5.
    1. Guaita M, Högl B. Current treatments of bruxism. Curr Treat Options Neurol. 2016;18:10.
    1. Alonso-Navarro H, Jiménez-Jiménez FJ, Plaza-Nieto JF, Pilo-De la Fuente B, Navacerrada F, Arroyo-Solera M. Treatment of severe bruxism with botulinum toxin type A. Rev Neurol. 2011;53:73–6.
    1. Finiels PJ, Batifol D. The use of botulinum toxin in the treatment of the consequences of bruxism on cervical spine musculature. Toxicon. 2014;80:58–63.
    1. Lavigne G, Kim JS, Valiquette C, Lund JP. Evidence that periodontal pressoreceptors provide positive feedback to jaw closing muscles during mastication. J Neurophysiol. 1987;58:342–58.
    1. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain inbruxers: a controlled placebo pilot study. Cranio. 2008;26:126–35.
    1. Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89:16–23.
    1. Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014;89:878–84.
    1. Borodic G. Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Facial Plast Surg Clin North Am. 2007;15:11–6,v.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir